VR Logo

Vericel Corporation (VCEL) download report


Healthcare | Biotechnology & Pharma Research

Vericel Corporation (VCEL) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States.

IPO Date: 04-Feb-1997

CEO, Pres & Director: Mr. Dominick C. Colangelo Esq.

CFO & Treasurer: Mr. Joseph Anthony Mara Jr.

Listing: NASDAQ: VCEL

Country: United States

Headquarters: Cambridge, MA

Website: https://vcel.com

Key Facts

Market cap: $1,451.67 Mln

Revenue (TTM): $157.69 Mln

Earnings (TTM): $-11.27 Mln

Cash: $100.55 Mln

Total Debt: $49.26 Mln

Insider's Holding: 0.71%

Liquidity: Low

52 Week range: $22.42 - 60.24

Shares outstanding: 47,119,900

10 Years Aggregate:

  • CFO: $-82.30 Mln
  • EBITDA: $-132.99 Mln
  • Net Profit: $-140.62 Mln

Stock Performance

Time Period Vericel (VCEL) S&P BSE Sensex* S&P Small-Cap 600*
YTD-21.701.02-11.58
1 month19.178.628.86
3 months-0.907.31-2.19
1 Year-37.438.42-6.23
3 Years18.4017.059.73
5 Years58.2512.767.72
10 Years-1.8812.8310.81
As on 05-Aug-2022 *As on 08-Aug-2022
Year Vericel (VCEL) S&P Small-Cap 600 S&P BSE Sensex
202127.2725.2721.99
202077.479.5715.75
20190.0020.8614.38
2018217.25-9.705.87
201781.6711.7327.91
201616.2824.741.95
2015-15.13-3.36-5.03